- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02094469
Safety and Efficacy Study of Cilostazol to Treat Vasospastic Angina (STELLA_Ext)
A Multicenter, One Group, Open-label Study to Evaluate the Safety and Efficacy of Pletaal(Cilostazol) as BID for up to 24 Weeks Exposure in Subjects With Vasospastic Angina (STELLA Extension)
This study will be conducted in accordance with the local regulation of New Drug Application. Overall duration of this trial will be 3 years after approval of MFDS.
Each subject will participate around 26 weeks, which include the 24 weeks treatment period and 2 weeks safety follow up period. Withdrawn subjects due to efficacy after 4 weeks treatment will participate in 6 weeks in total including 2 weeks safety follow up. Withdrawn subjects with other reason also have 2 weeks follow up period.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Busan, Korea, Republic of, 626-770
- Yangsan Busan University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects aged 20 to 80 years, and subjects whose age at the time of enrollment was 80 in 021-KOA-1301i clinical trial and is 81 in this clinical trial
- Subjects who completed 021-KOA-1301i clinical trial
- Women of childbearing potential with negative pregnancy test at enrollment and who agree to practice a contraceptive measure throughout the clinical trial (e.g., hormonal contraceptives, intrauterine devices, condom + spermicidal agents, diaphragm + spermicidal agents, and partner's infertility)
- Subjects who signed a written agreement indicating that they were given full explanations of the clinical trial and are willing to participate in the clinical trial
Exclusion Criteria:
- Subjects who fell under one of the exclusion criteria at the time of enrollment for 021-KOA-1301i
Subjects who reported any of the following events, which fall under the exclusion criteria for KOA-1301i, between the initiation of 021-KOA-1301i participation and enrollment visit for 021-KOA-1302i
- Myocardial infarction or myocardial infarction induced by vasospastic angina
- Life-threatening vasospastic episodes (e.g., ventricular tachycardia, ventricular fibrillation, or syncope)
- Stroke, intracranial hemorrhage, or transient ischemic attack (TIA)
- Hemorrhage (hemophilia, capillary fragility, intracranial hemorrhage, upper gastrointestinal bleeding, urinary tract bleeding, hemoptysis, vitreous hemorrhage, etc.)
- Subjects who are currently using any of the medications contraindicated in 021-KOA-1301i (excluding the investigational product of 021-KOA-1301i) at baseline
Subjects who meet the following criteria for baseline laboratory findings
- severe anemia with hemoglobin ≤6.5 g/dl at baseline
- Creatinine level ≥ 1.5 mg/dL at baseline
- AST or ALT >3x ULN at baseline
- Platelet count < 100,000mm3 at baseline
- Pulse rate exceeding 100 bpm when measured for vital signs at baseline: Tachycardia
- Hypotension with systolic pressure < 90mmHg at baseline
- Uncontrolled hypertension defined as systolic pressure ≥ 160 mmHg or diastolic pressure ≥ 100 mmHg at baseline
- QT prolongation defined as QTcB > 450 msec for men and QTcB > 470 msec for women at baseline
- Women of childbearing potential with positive pregnancy test at baseline
- Women who do not agree to practice a contraceptive measure, or are pregnant or lactating
- Subjects who are not expected to have the potential to benefit from additional administration of Cilostazol, according to the investigator's judgment
- Subjects otherwise judged by the investigator to be inappropriate for inclusion in the trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Cilostazol
Cilostazol 50mg and 100mg
|
Oral, Bid, 24 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of the subjects whose chest pain was not present in the final 1 week/2 weeks after the 24-week treatment period
Time Frame: 24 weeks
|
Proportion of the subjects whose chest pain was not present in the final 1 week/2 weeks after the 24-week treatment period
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
secondary 1
Time Frame: 24 week
|
Change/rate of change in the frequency of chest pain in the final 1week/2 weeks after the 24-week treatment period compared to those in the final 1 week/2weeks of Amlodipine run-in period in 021-KOA-1301i
|
24 week
|
secondary 2
Time Frame: 4 weeks
|
Mean change in the intensity of chest pain in the final 1 week/2 weeks after the 24-week treatment period compared to that in the final 1 week/2weeks of Amlodipine run-in period in 021-KOA-1301i
|
4 weeks
|
secondary 3
Time Frame: 4 weeks
|
4-week cumulative rate of subjects withdrawn due to lack of efficacy
|
4 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Junghong Kim, MD, Yangsan Busan University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Pain
- Neurologic Manifestations
- Chest Pain
- Angina, Unstable
- Angina Pectoris
- Angina Pectoris, Variant
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Neuroprotective Agents
- Protective Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Phosphodiesterase Inhibitors
- Phosphodiesterase 3 Inhibitors
- Cilostazol
Other Study ID Numbers
- 021-KOA-1302i
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vasospastic Angina
-
Roxane LaboratoriesCompletedHypertension | Vasospastic Angina | Chronic Stable AnginaUnited States
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentNot yet recruitingAngina Pectoris; Angiospastic
-
Dong-A UniversityUnknown
-
Tongji HospitalRecruiting
-
Korea Otsuka Pharmaceutical Co., Ltd.CompletedVasospastic AnginaKorea, Republic of
-
Roxane LaboratoriesCompletedHypertension | Vasospastic Angina | Chronic Stable AnginaUnited States
-
Dong-A UniversityUnknownSpasmKorea, Republic of
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaWithdrawnAngina Pectoris, Variant | Statins, HMG-CoAKorea, Republic of
-
Kosin University Gospel HospitalUnknown
-
Charite University, Berlin, GermanyDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)RecruitingCoronary Artery Disease | Microvascular Angina | Vasospastic Angina | Coronary Microvascular Dysfunction | Vasospasm, Coronary | Prinzmetal AnginaGermany, Switzerland
Clinical Trials on Cilostazol
-
Kobe City General HospitalOsaka University; Okayama University; Kobe University; Nagoya University; Kyoto University and other collaboratorsCompletedIn-stent Restenosis After Carotid Artery StentingJapan
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Mutual Pharmaceutical Company, Inc.CompletedTherapeutic Equivalency
-
Mutual Pharmaceutical Company, Inc.CompletedTherapeutic Equivalency, Healthy
-
Beijing Tiantan HospitalNeuroDawn Pharmaceutical Co., Ltd.Not yet recruitingAcute Ischemic Stroke | Large Vessel Occlusion | Reperfusion
-
University of EdinburghUniversity of Nottingham; British Heart FoundationCompletedCerebral Small Vessel Diseases | Stroke, LacunarUnited Kingdom
-
Noorik Biopharmaceuticals AGTerminatedCovid19 | HypoxemiaSpain, Croatia
-
Otsuka Beijing Research InstituteCompletedAtherosclerosis Cerebral InfarctionChina
-
CardioVascular Research Foundation, KoreaOtsuka KoreaCompletedCoronary Artery DiseaseKorea, Republic of